Competitors in one of the industry's fastest growing markets, the TNF-blocker class of rheumatoid arthritis drugs, have gained extensions to …
New legislation will be introduced to combat animal rights extremists' violence against those involved in using animals in medical research.But …
Biota, the Australian biotech company that discovered Relenza, is taking GlaxoSmithKline to court, alleging that it failed to properly launch …
A phase III trial of a drug to treat ovarian cancer has disappointed and is likely to be dropped, co-developers …
Aventis has dropped its long-running opposition to a takeover bid by French compatriots Sanofi-Synthlabo after the offer to its shareholders …
The government is shortly to announce the approval of the world's first over-the-counter statin, Zocor Heart Pro, but is unlikely …
Burson-Marsteller, a subsidiary of the WPP advertising giant, has been appointed PR campaign handler for the UK launch of Velcade, …
A new Roche-sponsored survey of patients with bowel cancer has found that most are still not being consulted on the …
The chairman of the BMA has warned that new reforms are adding to the threat of a two-tier NHS posed …
Aventis has unleashed its latest stratagem in resisting Sanofi-Synthleabo's hostile takeover bid, a US legal action claiming its rival has …
The first quarter of 2004 saw Pfizer’s biggest seller Lipitor extend its domination of the statin market but Viagra, another …
The FDA has approved Aventis' rapid-acting insulin analogue Apidra, ahead of an anticipated August approval by the EMEA, as the …
One year on from the launch of the National Service Framework (NSF) for Diabetes, the planning of care has improved …
Wyeth, manufacturers of the UK's biggest selling prescription drug Zoton plan to take the drug POM-P, hot on the heels …
The new General Medical Services contract (nGMS) started officially on 1st April, though its far-reaching effects may be far from …
We are all familiar with the growth of the ageing population during the second half of the 20th century and …